Postoperative Radiotherapy for Resected Pathological Stage IIIA-N2 Non-small Cell Lung Cancer: a Retrospective Study of 221 Cases from a Single Institution

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2011 Apr 13

PMID 21482587

Citations 45

Authors

Honghai Dai

Zhouguang Hui

Wei Ji

Jun Liang

Jima Lu

Guangfei Ou

Zongmei Zhou

Qinfu Feng

Zefen Xiao

Dongfu Chen

Hongxing Zhang

Weibo Yin

Jie He

Luhua Wang

Affiliations

Soon will be listed here.

Abstract

Background: For patients with resected pathological stage IIIA-N2 non-small cell lung cancer (NSCLC), the role of postoperative radiotherapy (PORT) is not well defined. In this single-institutional study, we re-evaluated the effect of PORT on overall survival (OS) as well as tumor control in this subgroup of patients.

Methods: In 2003-2005, 221 consecutive patients with resected pathological stage IIIA-N2 NSCLC at our institution were retrospectively analyzed in an institutional review board-approved study. The effect of PORT on OS, cancer-specific survival (CSS), and disease-free survival (DFS) was evaluated using the Kaplan-Meier method and log-rank tests. The impact of PORT on locoregional control and distant metastasis was also analyzed. Results. Compared with the control, patients treated with PORT had a significantly longer OS time (χ2, 3.966; p = .046) and DFS interval (χ2, 6.891; p = .009), as well as a trend toward a longer CSS duration (χ2, 3.486; p = .062). Patients treated with PORT also had a significantly higher locoregional recurrence-free survival rate (χ2, 5.048; p = .025) as well as distant metastasis-free survival rate (χ2, 11.248; p = .001). Multivariate analyses showed that PORT was significantly associated with a longer OS duration (p = .000).

Conclusions: PORT can significantly improve the survival of patients with resected pathological stage IIIA-N2 NSCLC. A prospective randomized multicenter clinical trial is ongoing.

Citing Articles

Preoperative CT-based radiomic prognostic index to predict the benefit of postoperative radiotherapy in patients with non-small cell lung cancer: a multicenter study.

Ma Z, Men Y, Liu Y, Bao Y, Liu Q, Yang X Cancer Imaging. 2024; 24(1):61.

PMID: 38741207 PMC: 11089675. DOI: 10.1186/s40644-024-00707-6.

Clinical impact of postoperative radiotherapy in pIII-N2 non-small cell lung cancer after complete resection followed by adjuvant chemotherapy: a systematic review and meta-analysis.

Kim I, Yun J J Thorac Dis. 2024; 16(3):1815-1824.

PMID: 38617755 PMC: 11009594. DOI: 10.21037/jtd-23-1742.

Role of Postoperative Radiotherapy on High-Risk Stage pIIIA-N2 Non-Small Cell Lung Cancer Patients After Complete Resection and Adjuvant Chemotherapy: A Retrospective Cohort Study.

Chen Z, Liang H, Liu Y, Huang W, Pan X World J Oncol. 2024; 15(2):309-318.

PMID: 38545478 PMC: 10965260. DOI: 10.14740/wjon1832.

Recurrence/prognosis estimation using a molecularly positive surgical margin-based model calls for alternative curative strategies in pIIIA/N2 NSCLC.

Li L, He K, Zhou T, Xu Y, Pang J, Yu Q Mol Oncol. 2024; 18(6):1649-1664.

PMID: 38327028 PMC: 11161728. DOI: 10.1002/1878-0261.13600.

Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer.

Kim B, Kim J, Kim H Radiat Oncol J. 2023; 41(3):144-153.

PMID: 37793623 PMC: 10556840. DOI: 10.3857/roj.2023.00430.

References

Keller S, Adak S, Wagner H, Herskovic A, Komaki R, Brooks B . A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med. 2000; 343(17):1217-22. DOI: 10.1056/NEJM200010263431703. View

Le Pechoux C, Dunant A, Pignon J, De Ruysscher D, Mornex F, Senan S . Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement. J Clin Oncol. 2007; 25(7):e10-1. DOI: 10.1200/JCO.2006.09.6263. View

Stephens R, Girling D, Bleehen N, Moghissi K, Yosef H, Machin D . The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1996; 74(4):632-9. PMC: 2074683. DOI: 10.1038/bjc.1996.413. View

Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y . The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg. 1999; 118(1):145-53. DOI: 10.1016/S0022-5223(99)70153-4. View

Moretti L, Yu D, Chen H, Carbone D, Johnson D, Keedy V . Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. Oncologist. 2009; 14(11):1106-15. PMC: 3045762. DOI: 10.1634/theoncologist.2009-0130. View

Dautzenberg B, Arriagada R, Chammard A, Jarema A, Mezzetti M, Mattson K . A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer. 1999; 86(2):265-73. DOI: 10.1002/(sici)1097-0142(19990715)86:2<265::aid-cncr10>3.0.co;2-b. View

Bekelman J, Rosenzweig K, Bach P, Schrag D . Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 66(2):492-9. DOI: 10.1016/j.ijrobp.2006.04.032. View

Scotti V, Meattini I, Saieva C, Agresti B, De Luca Cardillo C, Bastiani P . Post-operative radiotherapy in N2 non-small cell lung cancer: a retrospective analysis of 175 patients. Radiother Oncol. 2010; 96(1):84-8. DOI: 10.1016/j.radonc.2010.05.010. View

Uno T, Sumi M, Kihara A, Numasaki H, Kawakami H, Ikeda H . Postoperative radiotherapy for non-small-cell lung cancer: results of the 1999-2001 patterns of care study nationwide process survey in Japan. Lung Cancer. 2007; 56(3):357-62. DOI: 10.1016/j.lungcan.2007.01.017. View

10.

Machtay M, Lee J, Shrager J, Kaiser L, Glatstein E . Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol. 2001; 19(19):3912-7. DOI: 10.1200/JCO.2001.19.19.3912. View

11.

Douillard J, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba J . Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7(9):719-27. DOI: 10.1016/S1470-2045(06)70804-X. View

12.

Casali C, Stefani A, Natali P, Rossi G, Morandi U . Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg. 2005; 28(1):33-8. DOI: 10.1016/j.ejcts.2005.03.016. View

13.

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C . Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 352(25):2589-97. DOI: 10.1056/NEJMoa043623. View

14.

Wakelee H, Stephenson P, Keller S, Wagner H, Herskovic A, Komaki R . Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology.... Lung Cancer. 2005; 48(3):389-97. DOI: 10.1016/j.lungcan.2004.11.007. View

15.

Munro A . What now for postoperative radiotherapy for lung cancer?. Lancet. 1998; 352(9124):250-1. DOI: 10.1016/S0140-6736(98)22030-7. View

16.

Bradley J, Graham M, Winter K, Purdy J, Komaki R, Roa W . Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005; 61(2):318-28. DOI: 10.1016/j.ijrobp.2004.06.260. View

17.

. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med. 1986; 315(22):1377-81. DOI: 10.1056/NEJM198611273152202. View

18.

Bradley J, Paulus R, Graham M, Ettinger D, Johnstone D, Pilepich M . Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. J Clin Oncol. 2005; 23(15):3480-7. DOI: 10.1200/JCO.2005.12.120. View

19.

Martini N, Flehinger B . The role of surgery in N2 lung cancer. Surg Clin North Am. 1987; 67(5):1037-49. DOI: 10.1016/s0039-6109(16)44341-0. View

20.

Zou B, Xu Y, Li T, Li W, Tang B, Zhou L . A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease. Int J Radiat Oncol Biol Phys. 2009; 77(2):321-8. DOI: 10.1016/j.ijrobp.2009.05.044. View